Key result
Cardiac rehabilitation in HF and CAD involves epigenetic mechanisms and non-coding RNAs offering novel therapeutic targets.
Why the study?
Pre- and clinical cardiac rehabilitation models provide potential beneficial mechanisms to exploit for therapy, motivating an exploration of the epigenetic mechanisms involved and their translational relevance.
This review highlights the epigenetic mechanisms, such as non-coding RNAs, underlying the benefits of cardiac rehabilitation in heart failure and coronary artery disease, suggesting their potential as therapeutic targets and predictive biomarkers.
Should not yet change cardiac rehabilitation practice; leaves open epigenetic targets and biomarkers for prospective validation.
The benefits of cardiac rehabilitation (CR) have been demonstrated in patients after myocardial infarction (MI), and in patients with chronic heart failure (HF). The core components of the CR program include improvement in exercise tolerance and optimization of coronary risk factors (i.e., lipid and lipoprotein profiles, body weight, blood glucose levels, blood pressure levels, and smoking cessation). Indeed, CR has been shown to improve exercise capacity, control of cardiovascular risk factors, quality of life, hospital readmission, and mortality rates. Nonetheless, pre- and clinical CR and exercise training models are an enormous source of potential beneficial mechanisms that can be exploited for cardiac disease therapy. Consequently, in this review, we aim to explore the unique benefits of CR in HF and coronary artery disease, focusing on the epigenetic mechanisms involved and their translational relevance. These mechanisms may represent novel therapeutic targets to promote functional recovery after cardiac injury, and non-coding RNAs could be predictive biomarkers for CR success in patients.
No takes yet. Share an insight, caveat, or question.
Visco et al. (2025) conducted a review in Heart failure and coronary artery disease. Cardiac rehabilitation was evaluated. Cardiac rehabilitation in heart failure and coronary artery disease involves epigenetic mechanisms and non-coding RNAs that may represent novel therapeutic targets and predictive biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: